Summary：**Anti-Obesity Drug Market Soaring Toward $70.3B by 2035, Analysts Predict** The global fight again

referrerpolicy="no-referrer"
style="max-width:100%;height:auto;display:block;margin:0 auto;">

**Anti-Obesity Drug Market Soaring Toward $70.3B by 2035, Analysts Predict**

The global fight against obesity is entering a new phase as pharmaceutical breakthroughs reshape treatment pathways. Analysts forecast that the combined anti‑obesity drugs market will reach roughly $70.3 billion by 2035, driven by surging demand in the United States and Europe. In the U.S., sales are expected to climb from $2.27 billion in 2025 to $19.64 billion a decade later, while Europe’s market should grow from $1.88 billion to $16.94 billion over the same period. The expansion hinges on wider adoption of GLP‑1 receptor agonists, broader insurance coverage, and rising awareness of obesity‑related health risks.

**Key Developments**
Recent regulatory approvals for next‑generation GLP‑1 agents, such as tirzepatide and semaglutide formulations, have demonstrated weight‑loss efficacy exceeding 15 % in clinical trials. These results have prompted major insurers to revisit reimbursement criteria, moving from restrictive criteria to more inclusive policies that cover patients with a body mass index (BMI) of 30 kg/m² or higher, or 27 kg/m² with comorbidities. Simultaneously, pharmaceutical companies are investing heavily in manufacturing capacity to meet anticipated demand, with several new production lines slated for operation by 2027. Partnerships between drug makers and digital health platforms